Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Decreased platelet size is associated with platelet activation and anti-phospholipid syndrome in systemic lupus erythematosus

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Lood, C, Tydén, H, Gullstrand, B, Nielsen, CT, Heegaard, NHH, Linge, P, Jönsen, A, Hesselstrand, R, Kahn, R & Bengtsson, AA 2017, 'Decreased platelet size is associated with platelet activation and anti-phospholipid syndrome in systemic lupus erythematosus' Rheumatology (Oxford, England), bind 56, nr. 3, s. 408-416. https://doi.org/10.1093/rheumatology/kew437

APA

CBE

MLA

Vancouver

Author

Lood, Christian ; Tydén, Helena ; Gullstrand, Birgitta ; Nielsen, Christoffer T ; Heegaard, Niels H H ; Linge, Petrus ; Jönsen, Andreas ; Hesselstrand, Roger ; Kahn, Robin ; Bengtsson, Anders A. / Decreased platelet size is associated with platelet activation and anti-phospholipid syndrome in systemic lupus erythematosus. I: Rheumatology (Oxford, England). 2017 ; Bind 56, Nr. 3. s. 408-416.

Bibtex

@article{0396aa13f36049899ae3abd3b1db9158,
title = "Decreased platelet size is associated with platelet activation and anti-phospholipid syndrome in systemic lupus erythematosus",
abstract = "Objectives: . SLE is an autoimmune disease with increased cardiovascular morbidity and platelet activation. In the general population, increased platelet size predicts platelet reactivity and cardiovascular disease. The aim of this study was to investigate whether platelet size related to platelet activation and cardiovascular disease in SLE.Methods: . Fresh blood samples from SLE patients ( n = 148), healthy volunteers ( n = 79) and disease controls ( n = 40) were analysed for platelet size and activation by flow cytometry, ELISA and cell count. Associations to manifest cardiovascular disease, venous thrombosis and APS were adjusted for traditional cardiovascular risk factors using logistic regression analysis.Results: . SLE patients had decreased platelet size as compared with healthy controls ( P = 0.003). In SLE, decreased platelet size was related to increased platelet activation, in particular microparticle formation ( P < 0.0001, r = -0.46) and release of serotonin from dense granules ( P < 0.001, r = 0.57). SLE patients with aCL had decreased platelet size ( P = 0.02) and aCL decreased platelet size in vitro ( P = 0.007). In contrast to the general population, increased platelet size was not associated with cardiovascular disease. Instead, decreased platelet size was associated with secondary APS, even after adjusting for traditional cardiovascular risk factors ( P = 0.01, odds ratio 3.58).Conclusion: . Platelet size is decreased in SLE patients and associated with microparticle formation and APS. Future studies are needed to determine the underlying mechanism(s) as well as the potential predictive value of small platelets for disease complications in SLE.",
keywords = "Adult, Aged, Aged, 80 and over, Antibodies, Anticardiolipin, Antiphospholipid Syndrome, Arthritis, Rheumatoid, Blood Platelets, Cardiovascular Diseases, Case-Control Studies, Cell Count, Cell-Derived Microparticles, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Humans, Logistic Models, Lupus Erythematosus, Systemic, Male, Middle Aged, Odds Ratio, Platelet Activation, Risk Factors, Scleroderma, Systemic, Serotonin, Venous Thrombosis, Young Adult, Journal Article",
author = "Christian Lood and Helena Tyd{\'e}n and Birgitta Gullstrand and Nielsen, {Christoffer T} and Heegaard, {Niels H H} and Petrus Linge and Andreas J{\"o}nsen and Roger Hesselstrand and Robin Kahn and Bengtsson, {Anders A}",
year = "2017",
month = "3",
day = "1",
doi = "10.1093/rheumatology/kew437",
language = "English",
volume = "56",
pages = "408--416",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "3",

}

RIS

TY - JOUR

T1 - Decreased platelet size is associated with platelet activation and anti-phospholipid syndrome in systemic lupus erythematosus

AU - Lood, Christian

AU - Tydén, Helena

AU - Gullstrand, Birgitta

AU - Nielsen, Christoffer T

AU - Heegaard, Niels H H

AU - Linge, Petrus

AU - Jönsen, Andreas

AU - Hesselstrand, Roger

AU - Kahn, Robin

AU - Bengtsson, Anders A

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Objectives: . SLE is an autoimmune disease with increased cardiovascular morbidity and platelet activation. In the general population, increased platelet size predicts platelet reactivity and cardiovascular disease. The aim of this study was to investigate whether platelet size related to platelet activation and cardiovascular disease in SLE.Methods: . Fresh blood samples from SLE patients ( n = 148), healthy volunteers ( n = 79) and disease controls ( n = 40) were analysed for platelet size and activation by flow cytometry, ELISA and cell count. Associations to manifest cardiovascular disease, venous thrombosis and APS were adjusted for traditional cardiovascular risk factors using logistic regression analysis.Results: . SLE patients had decreased platelet size as compared with healthy controls ( P = 0.003). In SLE, decreased platelet size was related to increased platelet activation, in particular microparticle formation ( P < 0.0001, r = -0.46) and release of serotonin from dense granules ( P < 0.001, r = 0.57). SLE patients with aCL had decreased platelet size ( P = 0.02) and aCL decreased platelet size in vitro ( P = 0.007). In contrast to the general population, increased platelet size was not associated with cardiovascular disease. Instead, decreased platelet size was associated with secondary APS, even after adjusting for traditional cardiovascular risk factors ( P = 0.01, odds ratio 3.58).Conclusion: . Platelet size is decreased in SLE patients and associated with microparticle formation and APS. Future studies are needed to determine the underlying mechanism(s) as well as the potential predictive value of small platelets for disease complications in SLE.

AB - Objectives: . SLE is an autoimmune disease with increased cardiovascular morbidity and platelet activation. In the general population, increased platelet size predicts platelet reactivity and cardiovascular disease. The aim of this study was to investigate whether platelet size related to platelet activation and cardiovascular disease in SLE.Methods: . Fresh blood samples from SLE patients ( n = 148), healthy volunteers ( n = 79) and disease controls ( n = 40) were analysed for platelet size and activation by flow cytometry, ELISA and cell count. Associations to manifest cardiovascular disease, venous thrombosis and APS were adjusted for traditional cardiovascular risk factors using logistic regression analysis.Results: . SLE patients had decreased platelet size as compared with healthy controls ( P = 0.003). In SLE, decreased platelet size was related to increased platelet activation, in particular microparticle formation ( P < 0.0001, r = -0.46) and release of serotonin from dense granules ( P < 0.001, r = 0.57). SLE patients with aCL had decreased platelet size ( P = 0.02) and aCL decreased platelet size in vitro ( P = 0.007). In contrast to the general population, increased platelet size was not associated with cardiovascular disease. Instead, decreased platelet size was associated with secondary APS, even after adjusting for traditional cardiovascular risk factors ( P = 0.01, odds ratio 3.58).Conclusion: . Platelet size is decreased in SLE patients and associated with microparticle formation and APS. Future studies are needed to determine the underlying mechanism(s) as well as the potential predictive value of small platelets for disease complications in SLE.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antibodies, Anticardiolipin

KW - Antiphospholipid Syndrome

KW - Arthritis, Rheumatoid

KW - Blood Platelets

KW - Cardiovascular Diseases

KW - Case-Control Studies

KW - Cell Count

KW - Cell-Derived Microparticles

KW - Enzyme-Linked Immunosorbent Assay

KW - Female

KW - Flow Cytometry

KW - Humans

KW - Logistic Models

KW - Lupus Erythematosus, Systemic

KW - Male

KW - Middle Aged

KW - Odds Ratio

KW - Platelet Activation

KW - Risk Factors

KW - Scleroderma, Systemic

KW - Serotonin

KW - Venous Thrombosis

KW - Young Adult

KW - Journal Article

U2 - 10.1093/rheumatology/kew437

DO - 10.1093/rheumatology/kew437

M3 - Journal article

VL - 56

SP - 408

EP - 416

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 3

ER -

ID: 52386669